TrialDiabetes care2026

suPAR Identifies Treatment-Resistant Inflammatory Risk Beyond hs-CRP in Type 2 Diabetes With Coronary Artery Disease: An Ancillary Analysis of BARI 2D.

Anis Ismail et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.